295 related articles for article (PubMed ID: 15625745)
1. Rofecoxib, Merck, and the FDA.
Villalba L; Witter J
N Engl J Med; 2004 Dec; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625745
[No Abstract] [Full Text] [Related]
2. Rofecoxib, Merck, and the FDA.
Kim PS; Reicin AS
N Engl J Med; 2004 Dec; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625342
[No Abstract] [Full Text] [Related]
3. Rofecoxib, Merck, and the FDA.
Wolfe MM
N Engl J Med; 2004 Dec; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625749
[No Abstract] [Full Text] [Related]
4. Vioxx's history and the need for better procedures and better testing.
Gilhooley M
Seton Hall Law Rev; 2007; 37(4):941-68. PubMed ID: 18363218
[No Abstract] [Full Text] [Related]
5. Failing the public health--rofecoxib, Merck, and the FDA.
Topol EJ
N Engl J Med; 2004 Oct; 351(17):1707-9. PubMed ID: 15470193
[No Abstract] [Full Text] [Related]
6. Under surveillance.
Nat Biotechnol; 2005 Jan; 23(1):1. PubMed ID: 15637596
[No Abstract] [Full Text] [Related]
7. Learning the value of drugs--is rofecoxib a regulatory success story?
Eisenberg RS
N Engl J Med; 2005 Mar; 352(13):1285-7. PubMed ID: 15800222
[No Abstract] [Full Text] [Related]
8. Raising the safety bar--the FDA's coxib meeting.
Okie S
N Engl J Med; 2005 Mar; 352(13):1283-5. PubMed ID: 15800221
[No Abstract] [Full Text] [Related]
9. The lessons of Vioxx.
Frazier KC
N Engl J Med; 2005 Sep; 353(13):1420-1; author reply 1420-1. PubMed ID: 16192497
[No Abstract] [Full Text] [Related]
10. Cyclooxygenase-2 inhibitors and cardiovascular risk.
Smith ER
Can J Cardiol; 2005 Mar; 21(3):307-8. PubMed ID: 15776124
[No Abstract] [Full Text] [Related]
11. Vioxx, the implosion of Merck, and aftershocks at the FDA.
Horton R
Lancet; 2004 Dec 4-10; 364(9450):1995-6. PubMed ID: 15582041
[No Abstract] [Full Text] [Related]
12. The Vioxx debacle revisited.
Mohapatra PR; Janmeja AK
Am J Med; 2005 Sep; 118(9):1058. PubMed ID: 16164909
[No Abstract] [Full Text] [Related]
13. What ails the FDA?
Okie S
N Engl J Med; 2005 Mar; 352(11):1063-6. PubMed ID: 15784660
[No Abstract] [Full Text] [Related]
14. The Vioxx debacle revisited.
Manthous CA
Am J Med; 2005 Sep; 118(9):1056-7; author reply 1057. PubMed ID: 16164904
[No Abstract] [Full Text] [Related]
15. How to avoid future Vioxx-type scandals.
Prescrire Int; 2005 Jun; 14(77):115-7. PubMed ID: 15984108
[TBL] [Abstract][Full Text] [Related]
16. The Vioxx debacle revisited.
Daikh DI
Am J Med; 2005 Sep; 118(9):1057. PubMed ID: 16164908
[No Abstract] [Full Text] [Related]
17. Discontinuation of Vioxx.
Garattini S; Bertelé V
Lancet; 2005 Jan 1-7; 365(9453):24. PubMed ID: 15639671
[No Abstract] [Full Text] [Related]
18. FDA warns Merck over its promotion of rofecoxib.
Josefson D
BMJ; 2001 Oct; 323(7316):767. PubMed ID: 11588068
[No Abstract] [Full Text] [Related]
19. The coxib conundrum: lessons from the rise and fall of rofecoxib.
Whelton A
Am J Ther; 2004; 11(6):417-21. PubMed ID: 15543079
[No Abstract] [Full Text] [Related]
20. Safety, scrutiny and conflicts: assessing the fallout and lessons learned from pharmaceuticals.
Lanzafame RJ
Photomed Laser Surg; 2005 Feb; 23(1):1-2. PubMed ID: 15782023
[No Abstract] [Full Text] [Related]
[Next] [New Search]
